Andrew Cittadine Acquires 12,000 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Andrew Cittadine bought 12,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The shares were bought at an average cost of $0.91 per share, with a total value of $10,920.00. Following the purchase, the chief operating officer now directly owns 129,624 shares in the company, valued at $117,957.84. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Andrew Cittadine also recently made the following trade(s):

• On Monday, June 17th, Andrew Cittadine bought 12,000 shares of Monopar Therapeutics stock. The shares were bought at an average cost of $0.90 per share, with a total value of $10,800.00.
• On Monday, June 3rd, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.76 per share, for a total transaction of $9,120.00.
• On Friday, May 31st, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.64 per share, for a total transaction of $7,680.00.
• On Wednesday, May 29th, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.64 per share, for a total transaction of $7,680.00.

Monopar Therapeutics Stock Performance

Shares of NASDAQ:MNPR traded down $0.07 on Monday, hitting $0.87. 95,174 shares of the company were exchanged, compared to its average volume of 2,991,488. The company’s 50 day moving average price is $0.70 and its two-hundred day moving average price is $0.59. Monopar Therapeutics Inc. has a one year low of $0.27 and a one year high of $1.73. The firm has a market capitalization of $15.22 million, a price-to-earnings ratio of -1.67 and a beta of 1.15.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. Research analysts predict that Monopar Therapeutics Inc. will post -0.37 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Jonestrading upgraded shares of Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Thursday, April 11th. HC Wainwright restated a “buy” rating and set a $2.00 price target on shares of Monopar Therapeutics in a report on Friday, May 10th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.